Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Ritlecitinib for the Treatment of Patients with Cutaneous T Cell Lymphomas

Trial Status: closed to accrual

This phase IIA trial tests the safety and effectiveness of ritlecitinib for the treatment of patients with cutaneous T cell lymphomas (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin (cutaneous). Ritlecitinib may stop the growth of abnormal cells by blocking an enzyme needed for cell growth. Giving ritlecitinib may kill more tumor cells in patients with cutaneous T cell lymphomas.